Takotsubu Cardiomyopathy Patient With Coronary Artery Disease: The Chicken or the Egg.

This case emphasizes the rare occurrence of Takotsubo cardiomyopathy (TTC) in a patient with moderate coronary artery disease (CAD), highlighting the complexity of diagnosis and management. Clinicians should maintain a high index of suspicion for TTC in patients with CAD, especially when echocardiographic findings suggest apical ballooning. Balancing therapies for both conditions is essential.

Rational design and synthesis of novel phenyltriazole derivatives targeting MRSA cell wall biosynthesis.

Antimicrobial resistance in methicillin-resistant (MRSA) is a major global health challenge. This study reports the design and synthesis of novel phenyltriazole derivatives as potential anti-MRSA agents. The new scaffold replaces the thiazole core with a 1,2,3-triazole ring, enhancing antimicrobial efficacy and physicochemical properties.

The prevalence and clinical significance of EGFR mutations in non-small cell lung cancer patients in Egypt: a screening study.

Background: Lung cancer is a form of cancer that is responsible for the largest incidence of deaths attributed to cancer worldwide. Non-small cell lung cancer (NSCLC) is the most prevalent of all the subtypes of the disease. Treatment with tyrosine kinase inhibitors (TKI) may help some people who have been diagnosed with non-small cell lung cancer.

Efficacy and Safety of Farletuzumab in Ovarian Cancer: A Systematic Review and Single-Arm Meta-Analysis.

Folate receptor alpha (FRα) has emerged as a promising target in the treatment of ovarian cancer, with farletuzumab, a humanized monoclonal antibody targeting FRα, showing potential in clinical settings. This systematic review and single-arm meta-analysis aimed to evaluate the efficacy and safety of farletuzumab in patients with solid tumors, particularly ovarian cancer. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a thorough search across PubMed, the Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) for clinical trials assessing farletuzumab in solid tumors.

Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals.

Unlabelled: The COVID-19 pandemic has emphasized the importance and need for accessible safe, effective, and versatile vaccine platforms. While approved SARS-CoV-2 vaccines have been instrumental in saving lives and reducing healthcare and economic burdens, the induction of mucosal immunity remains an unmet need. Here, we engineered and evaluated a non-replicating adenovirus 5 (rAd5)-based vaccine expressing the SARS-CoV-2 S1 subunit (rAd5-SARS2-S1).